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In host animals, adeno-associated virus (AAV) is detectable mainly in the lymphoid tissue, which appears to be a target in natural infection. We
used the human monocytic cell lines THP-1 and U937 to study the effect of mouse anti-AAV2 antiserum on infection with an AAV2 vector having
the luciferase gene (AAV2/Luc). AAV2/Luc was found to infect THP-1 and U937 cells much less efficiently than HeLa cells, as monitored with
the induced enzyme activity. Pre-incubation of AAV2/Luc with anti-AAV2 antiserum at a sub-neutralizing concentration enhanced by 2-to-10 fold
infection of THP-1 and U937 with AAV2/Luc, but not of HeLa. Similarly, anti-AAV10 serum at a low level enhanced infection of THP-1 with
AAV10/Luc. Sera of two cynomolgus monkeys, which had been probably infected with an AAV2-like virus, enhanced infection of THP-1 with
AAV2/Luc. The enhancement was reduced with blocking the IgG-receptors Fcγ-RI and Fcγ-RII, which were displayed on the surface of THP-1
and U937 but not HeLa cells, with anti-Fcγ-RI antibody or anti-Fcγ-RII antibody. The data indicate that infection of Fcγ receptor-bearing cells
with AAV is enhanced by anti-AAV IgG antibodies at a sub-neutralizing concentration that play a role in linking AAV particles and Fcγ receptors.
© 2008 Elsevier Inc. All rights reserved.Keywords: AAV; Anti-AAV antibody; ADE; Fcγ-receptorIntroduction
Adeno-associated virus (AAV) is a nonenveloped icosahe-
dral particle (a diameter of 25 nm) containing a single-
stranded linear DNA (4.7 kb). To date several AAV serotypes
and over 100 AAV variants have been recorded (Wu et al.,
2006). Among them AAV serotype type 2 (AAV2) has been
studied most extensively and used for gene therapy trials.
Efficient propagation of AAV2 in cultured cells requires
coinfection with a helper virus (Carter et al., 1979;
Richardson and Westphal, 1981; Buller et al., 1981;
McPherson et al., 1985). Without a helper virus the AAV
DNA is integrated into cell DNA at a specific site and
maintained as a provirus (Flotte and Berns, 2005). When a
latently infected cell is super-infected with adenovirus, the
integrated AAV is induced to replicate (Handa et al., 1977;⁎ Corresponding author. Fax: +81 3 5285 1166.
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doi:10.1016/j.virol.2008.01.033Cheung et al., 1980). A low level induction has been
observed upon Fas-mediated apoptosis of the latently infected
cells (Mori et al., 2002).
The tissue tropism of AAV in natural infection is not fully
elucidated. AAV10, AAV11, and AAVcy.7 have been detected
mainly in the lymphoid tissue and ileum of the naturally infec-
ted cynomolgus monkeys (Mori et al., 2008). AAV2 vectors
injected to monkeys are detectable in the lymphoid tissue
(Conrad et al., 1996; Favre et al., 2001; Lai et al., 2002;
Nathwani et al., 2002; Davidoff et al., 2005; Mori et al., 2006)
and the leukocytes (Favre et al., 2001; Lai et al., 2002). These
studies suggest that the leukocytes are one of the major targets
for AAV.
Infection of the leukocytes with dengue virus (DENV) is
enhanced by either sub-neutralizing level of serotype-spe-
cific anti-DENV antibody or cross-reactive anti-DENV
antibody (Clyde et al., 2006). The antibody, which binds
to the virion at its variable region and to the cell-surface
Fcγ receptor (Fcγ-R) at its Fc-region, mediates attachment
of the virion to the surface of monocytes and macrophages
Fig. 1. Infection of THP-1, U937, and HeLa cells with AAV2/Luc. AAV2/Luc was
inoculated to the cells at three multiplicities of infection (gc/cell). Two days later,
the cells were lysed and luciferase activities of the lysates were measured. Each bar
represents the average of three independent experiments with the standard devia-
tion indicated by an error bar. RLU: relative light units.
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(ADE) of DENV is believed to be associated with dengue
hemorrhagic fever. Similar ADE has been reported in
infection of Fcγ-R-positive cells with West Nile virus
(Peiris and Porterfield, 1979; Peiris et al., 1981), human
parvovirus B19 (Munakata et al., 2006), and Aleutian mink
disease parvovirus (Kanno et al., 1993).
In this study we examined infection of THP-1 and U937,
human monocytic cell lines that were expressing Fcγ-R, with
recombinant AAV vectors that had been pre-incubated with
diluted anti-AAV antiserum and found that a sub-neutralizing
level of the antiserum enhanced infection of these cells with
AAV vectors.Fig. 2. Effect of anti-AAV2 antiserum on the infection of THP-1, U937, and HeLa cel
anti-AAV2 antiserum and incubated at 37 °C for 30 min. The mixtures were inoculate
(gc/cell) indicated. Two days later, the luciferase activity of the cellular lysate was mea
standard deviation indicated by an error bar. RLU: relative light units.Results
Antibody-dependent-enhancement of infection of THP-1 and
U937 cells with AAV2 and AAV10
Infection of THP-1 and U937, human monocytic cell lines,
with AAV2/Luc, a recombinant AAV having the luciferase
gene, was much less efficient than that of HeLa. Serially diluted
AAV2/Luc was inoculated to the cells and 2 days later the cells
were lysed and the luciferase activities of the lysates were
measured (Fig. 1). While the luciferase activity of the HeLa
culture inoculated with AAV2/Luc at a multiplicity of infection
(MOI) of 10 genome copies (gc) was 200,000 U, those of the
THP-1 and U937 cultures inoculated at an MOI of 40 gc were
2500 U and 1000 U, respectively.
Infection of THP-1 and U937 cells with AAV2/Luc was
enhanced by pre-incubation of AAV2/Luc with a sub-
neutralizing concentration of anti-AAV2 antiserum. AAV2/
Luc was incubated with mouse anti-AAV2 antiserum or mouse
normal serum at 37 °C for 30 min and then inoculated to 3×105
of THP-1 cells (at MOIs of 10, 20, and 40 gc), U937 cells (at
MOIs of 50, 100, and 200 gc), and HeLa cells (at MOIs of 1, 2,
and 4 gc). Two days later the luciferase activity of the cellular
lysate was measured. The antiserum diluted at 1:100 induced a
major decrease of the luciferase activities of the three cell lines,
indicating that AAV2/Luc was neutralized with the antiserum
(Figs. 2, A, B, and C). Although the antiserum diluted at 1:1000
induced a slight decrease of the luciferase activity of HeLa
(Fig. 2C), it induced increase of the luciferase activities of THP-
1 and of U937 (Figs. 2, A and B). The antiserum diluted at
1:10,000 and the normal mouse serum did not affect the luci-
ferase activities of the three cell lines (Fig. 2). Thus, the
antiserum diluted at 1:1000 enhanced infection of THP-1 and
U937 with AAV2/Luc, indicating that typical ADE occurred in
infection to these cells with AAV2.ls with AAV2/Luc. AAV2/Luc was mixed with the diluted nonimmune serum or
d to THP-1 (A), U937 (B), or HeLa (C) cells at various multiplicities of infection
sured. Each bar represents the average of three independent experiments with the
Fig. 3. Effect of anti-AAV10 antiserum on the infection of THP-1 cells with
AAV10/Luc. AAV10/Luc was mixed with the diluted nonimmune serum or anti-
AAV10 antiserum and incubated at 37 °C for 30 min. The mixtures were
inoculated to THP-1 cells at the multiplicity of infection (gc/cell) indicated. Two
days later, the luciferase activity of the cellular lysate was measured. Each bar
represents the average of three independent experiments with the standard
deviation indicated by an error bar. RLU: relative light units.
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ced by a sub-neutralizing concentration of anti-AAV10 serum.
AAV10/Luc pre-incubated with mouse anti-AAV10 serum was
inoculated to THP-1 (3×105 cells) at an MOI of 2000 gc and
the luciferase activity was measured as the experiments with
AAV2/Luc. The antiserum reduced the infectivity of AAV10/Luc
at a dilution of 1:100 but increased the infectivity at dilutions of
1:1000 and 1:10,000 (Fig. 3).
Anti-AAV2 and anti-AAV10 sera did not increase the infec-
tivity of AAV10/Luc and AAV2/Luc, respectively (Fig. 4),
indicating clearly that the antibody capable of binding to AAV
particles mediates the enhancement of infection of THP-1 cells
with AAV.
Two monkey sera enhanced infection of THP-1 cells with
AAV2/Luc. Sera were obtained from two healthy male cyno-Fig. 4. Requirement of type-specific antibody for ADE of infection of THP-1 cells w
incubated with the undiluted or diluted anti-AAV2 or anti-AAV10 antiserum and inoc
was measured. Each bar represents the average of three independent experiments wmolgus monkeys of 5 years of age. The pre-incubation of AAV2/
Luc with themonkey-A serum that had been undiluted or diluted at
1:10 reduced the infectivity of AAV2/Luc to HeLa and to THP-1
(Figs. 5, A and B), indicating that the serum contained antibody
capable of neutralizing AAV2. Pre-incubation of AAV2/Luc with
the monkey-A serum that had been diluted at 1:100 and 1:1000 did
not affect the infectivity to HeLa but it increased the infectivity to
THP-1 (Figs. 5, A and B). Similarly, pre-incubation of AAV2/Luc
with the undiluted monkey-B serum, which did not neutralize
AAV2/Luc (Fig. 5A), enhanced infection of THP-1 (Fig. 5B). The
data clearly indicate thatmonkey-B serumdiluted at 1:10 and 1:100
did not affect the infectivity of AAV2/Luc (Fig. 5B). The data
strongly suggest that the two monkeys had been probably infected
with AAV types antigenically related to AAV2 and the sub-
neutralizing levels of the antibodies in the sera enhanced infection
of THP-1 with AAV2/Luc.
Involvement of the cell-surface Fcγ-receptors (Fcγ-R) in the
ADE of AAV infection
Both Fcγ-RI and Fcγ-RII were present on the surface of
THP-1 and U937 cells. THP-1, U937, and HeLa cells were
incubated with anti-CD64 mouse monoclonal antibody (mAb)
recognizing Fcγ-RI or anti-CD32 mouse mAb recognizing Fcγ-
RII at 4 °C for 1 h. Then the mAb on the surface was detected
with labeled-goat anti-mouse IgG antibody by using a FACS.
Both mAbs clearly bound to the surface of THP-1 and U937
cells but did not bind to the surface of HeLa cells (Fig. 6).
Pretreatment of THP-1 and U937 with anti-CD64 mAb or
anti-CD32 mAb interfered with ADE in the infection of these
cells with AAV2/Luc. THP-1 and U937 cells were incubated
with anti-CD64 mAb (5 μg/ml) and/or anti-CD32 (5 μg/ml)
mAb at 4 °C for 1 h. The cells were inoculated with AAV2/Luc
that had been pre-incubated with the anti-AAV2 antiserum
diluted at 1:1000 and the luciferase activities of the lysates were
measured at 2 days after the inoculation. The level of the
enhancement of infection of both cell lines with AAV2/Luc was
reduced by pretreatment with mAbs (Fig. 7), indicating thatith AAV2/Luc and AAV10/Luc. AAV2/Luc (A) and AAV10/Luc (B) were pre-
ulated to THP-1 cells. Two days later, the luciferase activity of the cellular lysate
ith the standard deviation indicated by an error bar. RLU: relative light units.
Fig. 5. Effect of the two monkey sera on the infection of THP-1 and HeLa cells with AAV2/Luc. AAV2/Luc was pre-incubated with the undiluted or the diluted
cynomolgus monkey sera and inoculated to HeLa (A) or THP-1 (B) cells. Two days later, the luciferase activity of the cellular lysate was measured. Each bar represents
the average of three independent experiments with the standard deviation indicated by an error bar. RLU: relative light units.
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Anti-CD64 mAb was more effective than anti-CD32 mAb for
the reduction and the mixture of anti-CD64 and anti-CD32
mAbs completely abolished the enhancement.
Discussion
We demonstrated that infection of THP-1 and U937, human
monocytic cell lines, with AAV2/Luc was enhanced by the
sub-neutralizing concentration of anti-AAV2 antibody. Simi-
larly infection of THP-1 with AAV10/Luc was enhanced by
the sub-neutralizing concentration of anti-AAV10 antibody.Fig. 6. Presence of Fcγ-RI and Fcγ-RII on THP-1 and U937 cells. THP-1, U937,
antibodies followed by staining with the Alexa Fluor 488-conjugated goat anti-mouse
flow cytometer. The bold line (indicated with filled arrowheads) shows the distributi
shows the distribution of the fluorescence of the cells incubated with only the seconCell-surface Fcγ-RI and Fcγ-RII were required for the en-
hancement, indicating that the antibodies play a role in linking
the AAV particle and the Fcγ-R on the cell surface. A variety
of leukocytes are positive for Fcγ-RI (monocytes/macrophages,
dendritic cells, and neutrophils) and Fcγ-RII (monocytes/
macrophages, dendritic cells, neutrophils, B lymphocytes, and
mast cells)(Cohen-Solal et al., 2004). It is possible that infection
of these cells with AAV is enhanced with a low level of anti-AAV
antibodies in vivo.
The naturally infected AAV does not induce the strong
immune response of host animals. Although a great majority of
humans are infected with AAV2 during childhood, the sera ofand HeLa cells were incubated with anti-Fcγ-RI or anti-Fcγ-RII monoclonal
IgG secondary antibody. The fluorescence on the cells was measured by using a
on of the resultant fluorescence. The thin line (indicated with open arrowheads)
dary antibody.
Fig. 7. Inhibition of ADE of AAV2 infection with anti-Fcγ-RI and anti-Fcγ-RII antibodies. THP-1 (A) and U937 (B) cells were pre-incubated with anti-Fcγ-RI and/or
anti-Fcγ-RII mAbs. Then, AA2/Luc that had been incubated with anti-AAV2 antiserumwas inoculated to the cells. Two days later, the luciferase activity of the cellular
lysate was measured. Each bar represents the average of three independent experiments with the standard deviation indicated by an error bar. RLU: relative light units.
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antibodies simultaneously, indicating anti-AAV2 antibody
induced by the primary infection does not protect the hosts
from the secondary infection (Erles et al., 1999). Among human
sera positive for anti-AAV antibody, only 30% of the sera are
neutralizing (Chirmule et al., 1999). The level of anti-AAV
antibody in the serum of the host persistently infected with AAV
could be appropriate for the enhancement of AAV infection.
Indeed the undiluted monkey-B sera, whose level of neutraliz-
ing antibody was below the detectable level, enhanced infection
of THP-1 with AAV2/Luc (Fig. 5).
ADE is probably important for AAV to be maintained in host
animals. Because the chance for the AAV-infected cell to be
super-infected with the helper virus must be very rare in vivo,
AAV may survive with a low level autonomous propagation
induced by the Fas-mediated apoptosis of the host cell (Mori
et al., 2002). ADE may support infection of a new host cell,
mainly a leukocyte, with AAV.
Previous studies have shown that the capability of an
antibody to contribute to ADE is independent of neutralizing
activity. The monoclonal neutralizing antibodies against West
Nile virus and against Dengue virus (Pierson et al., 2007;
Yamanaka et al., 2008) and non-neutralizing antibodies against
human respiratory syncytial virus (Gimenez et al., 1996) en-
hance infection of FcR bearing cells with these viruses, res-
pectively. It is necessary to examine a panel of anti-AAV
monoclonal antibodies for their capability of contributing to
ADE and for their binding characteristics to AAV particles in
future studies.
ADE may be useful for ex vivo immunotherapy, which uses
antigen-presenting cells transduced with AAV vectors in vitro
(Ponnazhagan et al., 2001; Veron et al., 2007). Because the
antigen-presenting cells, such as monocytes and dendritic cells,
are positive for Fcγ-RI and Fcγ-RII, pre-incubation of the AAV
vectors with anti-AAV antibodies at a sub-neutralizing level,
would increase the efficiency of transduction.This is the first report showing the ADE of infection of Fcγ-
R-bearing cells with the dependovirus. ADE has been observed
in infection of Fcγ-R-bearing cells with the autonomous par-
voviruses, such as human parvovirus B19 (Munakata et al.,
2006) and Aleutian mink disease parvovirus (Kanno et al.,
1993). The Fcγ-R-mediated ADE of infection may be common
to those belonging to Parvoviridae.
Experimental Procedures
Cells
THP-1 and U937, human monocytic cell lines, were pur-
chased from American Type Culture Collection (Manassas,
VA). THP-1 was cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS) and 50 μM 2-β-mer-
captoethanol at 37 °C. U937 was cultured in RPMI 1640
medium supplemented with 10% FBS at 37 °C. HeLa cells that
had been adapted to the suspension condition were cultured in
suspension minimal essential medium (S-MEM) supplemented
with 10% FBS with gentle shaking at 37 °C.
AAV vectors
A vector plasmid pAAVLuc was packaged into the AAV2
and AAV10 capsids to produce AAV2/Luc and AAV10/Luc,
respectively, in HEK293 cells as described previously (Mori
et al., 2004). The pAAVLuc is composed of the 5′-inverted
terminal repeats (ITR) of AAV2, simian virus 40 early enhancer/
promoter, firefly luciferase gene, and 3′-ITR. AAV2/Luc and
AAV10/Luc were purified by heparin affinity column chroma-
tography (Auricchio et al., 2001) and CsCl equilibrium centri-
fugation (Mori et al., 2004), respectively. Genome copy
numbers of the vector stocks were measured by real-time
PCR with TaqMan probes for the firefly luciferase gene (Perkin-
Elmer Biosystems, Foster City, CA).
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Anti-AAV2 antiserum was obtained by an intramuscular
injection of purified AAV2 vector having β-galactosidase gene
(109 genome copies per mouse) to eight-week-old female
BALB/c mice. The serum was collected at 6 weeks after the
injection. Mouse anti-AAV10 serum was produced previously
by immunizing mice with VP2, one of three capsid proteins
(Mori et al., 2004). Mouse anti-CD64 and anti-CD32 mono-
clonal antibodies (BD Bioscience PharMingen, San Diego, CA)
were used in the detection and blocking of Fcγ-RI and Fcγ-RII,
respectively.
Monkey sera
Sera were obtained from two cynomolgus monkeys kept in
Tsukuba Primate Research Center, National Institute of Bio-
medical Innovation. The monkeys were sedated during col-
lection of blood by administration of Ketamine (10 mg/kg).
Animal studies were performed in accordance with the guide-
lines for animal experiments in the National Institute of Infec-
tious Diseases.
Assay for AAV infection
AAV vectors were suspended in phosphate-buffered saline
(PBS) containing 5% FBS. 15 μl of vector suspension was
mixed with an equal volume of the test serum that had been
heat-inactivated (56 °C for 30 min) and diluted with PBS, and
incubated at 37 °C for 30 min. The mixture was inoculated to
3×105 cells in a microtube. After incubation at 4 °C for 1 h with
occasional rocking, the cells were washed with culture medium
twice and resuspended in 780 μl of culture medium. The cell-
suspension was seeded in 3 wells (250 μl/well) of a 48-well
culture plate and incubated at 37 °C for 2 days. The cells were
harvested and lysed. Luciferase activity of the lysate was
measured by using Luciferase Assay System (Promega,
Madison,WI) and Mithras LB940 Multilabelreader (Berthold
Technologies, Bad Wildbad, Germany).
Flow cytometry
THP-1, U937, and HeLa cells were incubated with 2.5 μg/ml
of anti-CD64 or anti-CD32 monoclonal antibody in reaction
buffer (PBS containing 2% FBS) for 1 h at 4 °C. The cells were
washed with the buffer twice and incubated in the buffer
containing 2.5 μg/ml of Alexa Fluor 488-conjugated goat anti-
mouse IgG serum (Molecular Probes, Eugene, OR). The cells
were washed twice with the buffer and then fixed with 2%
paraformaldehyde in PBS. Fluorescence was measured using a
flow cytometer (BD FACSCalibur, Becton Dickinson, Franklin
Lakes, NJ).
Blocking of FcγR on THP-1 and U937 cells
THP-1 andU937 cells were incubatedwith the culture medium
containing 5 μg/ml of anti-CD64 (BD Bioscience PharMingen)and/or anti-CD32 (BD Bioscience PharMingen) at 4 °C for 1 h.
The cells were washed twice with the culture medium and used in
the assay for AAV infection.
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